Atropos Health Continues Commitment to Advancements in Oncology with Addition of Key Personnel

With growing demand for RWE in oncology for drug development and discovery and treatment, Atropos Health is adding oncology specific RWD, product features and experienced personnel to enhance experiences for clinicians and researchers

Atropos Health, the leader in generating personalized real-world evidence (RWE) from real-world clinical data, today announced key personnel and product features enhancing their Oncology solutions. The company previously announced the expansion of the Oncology MultiModal Network in the Atropos Evidence™ Network with the addition of Ontada’s community oncology real-world data (RWD).

In addition to the growth of the Atropos Evidence Network, Atropos Health is also adding key personnel to enhance the oncology focus:

• Cory D. Wiegert joins as Chief Operating Officer, bringing over 25 years of experience leading innovation and product development in enterprise software and healthcare IT including the launch of a cloud-based, AI-driven decision platform. His extensive background also includes overseeing the industry's largest dataset for value-based, specialty care at Integra Connect and leadership roles at CancerLinQ, IBM Watson Health, and Siebel Systems.
• Dr. Morgan Cheatham joins the Atropos Health Board of Directors as a Board Observer bringing extensive expertise as Partner and Head of Healthcare and Life Sciences for Breyer Capital, where he leads investments across various sectors, including AI. Previously at Bessemer Venture Partners, he spearheaded early-stage investments in companies like Abridge and Hinge Health. Cheatham is also pursuing a fellowship in Clinical Genetics at Harvard/Boston Children's, serves on the Editorial Team for NEJM AI and Board Director for Coalition for Health AI, and has published research on clinical AI and genetic medicine in leading journals.
• Jason Jones heads Data Science at Atropos Health bringing extensive experience as the former Chief Data Scientist at Health Catalyst and a Research Scientist and VP at Kaiser Permanente. His background also includes significant roles in medical informatics at Intermountain Healthcare and leadership positions at Bayer HealthCare and UnitedHealth Group.

"We’re investing heavily in both product and personnel when it comes to applying RWE to oncology practice and research and development," said Dr. Brigham Hyde, CEO and co-founder at Atropos Health. "Bringing on additional Oncology-specific expertise signals our further investment and commitment to advancing life saving treatments in oncology. "

Along with the Ontada partnership, existing partner Norstella is now also an additional source of RWD for the Oncology MultiModal network in the Atropos Evidence Network, further enhancing the market leading federated oncology evidence network.

About Atropos Health

Atropos Health is the developer of GENEVA OS™, the operating system for rapid healthcare evidence across a robust network of real-world data. Healthcare and life science organizations work with Atropos Health to close evidence gaps from bench to bedside, improving individual patient outcomes with data-driven care, expediting research that advances the field of medicine, and more. We aim to transform healthcare with timely, relevant real-world evidence.

To learn more about Atropos Health, visit www.atroposhealth.com or connect through LinkedIn or follow on X (Twitter) @AtroposHealth.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250530359989/en/